Local secretion of IL-12 augments the therapeutic impact of dendritic celletumor cell fusion vaccination

Journal of Surgical Research

Volumn 185, Issue 2, 2013, Pages 904-911

  Tan, Chunrui ^a   Dannull, Jens ^a   Nair, Smita K ^a   Ding, Enyu ^a   Tyler, Douglas S ^a,b   Pruitt, Scott K ^a,b   Lee, Walter T ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

Animal model; Dendritic cell; Electrofusion; ELISPOT; Fusion hybrids; Immunotherapy; Interleukin 12; Melanoma; T cell; Vaccine

Indexed keywords

DENDRITIC CELL TUMOR CELL FUSION VACCINE; DENDRITIC CELL VACCINE; INTERLEUKIN 12; INTERLEUKIN 12P70; UNCLASSIFIED DRUG; CANCER VACCINE; GAMMA INTERFERON; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFICACY; ELECTROFUSION (CELL); ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RANK SUM TEST; SPLEEN CELL; TUMOR CELL; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; DISEASE MODEL; GENETICS; HYBRID CELL; IMMUNOLOGY; LACTOSE OPERON; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; METABOLISM; PATHOLOGY; PROCEDURES; SECRETION (PROCESS); TRANSPLANTATION; TUMOR CELL LINE; VACCINATION; ELECTROFUSION; EXPERIMENTAL MELANOMA; FUSION HYBRIDS; IMMUNOTHERAPY; LUNG TUMOR; MELANOMA; METHODOLOGY; T LYMPHOCYTE;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FEMALE; HYBRID CELLS; INTERFERON-GAMMA; INTERLEUKIN-12; LAC OPERON; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; VACCINATION;

ANIMAL MODEL; DENDRITIC CELL; ELECTROFUSION; ELISPOT; FUSION HYBRIDS; IMMUNOTHERAPY; INTERLEUKIN 12; MELANOMA; T CELL; VACCINE;

EID: 84891672797     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2013.06.045     Document Type: Article

References (41)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245.
2. Schuler G, Schuler-Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003;15:138.
3. Lee WT, Shimizu K, Kuriyama H, et al. Tumor-dendritic cell fusion as a basis for cancer immunotherapy. Otolaryngol Head Neck Surg 2005;132:755.
4. Shu S, Zheng R, Lee WT, Cohen PA. Immunogenicity of dendritic-tumor fusion hybrids and their utility in cancer immunotherapy. Crit Rev Immunol 2007;27:463.
5. Hayashi T, Tanaka H, Tanaka J, et al. Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion. Clin Immunol 2002;104:14.
6. Koido S, Hara E, Homma S, et al. Cancer vaccine by fusions of dendritic and cancer cells. Clin Dev Immunol 2009;2009: 657369.
7. Curtsinger JM, Lins DC, Mescher MF. Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med 2003;197:1141.
8. Homma S, Kikuchi T, Ishiji N, et al. Cancer immunotherapy by fusions of dendritic and tumour cells and rh-IL-12. Eur J Clin Invest 2005;35:279.
9. Kuriyama H, Shimizu K, Lee W, et al. Therapeutic vaccine generated by electrofusion of dendritic cells and tumour cells. Dev Biol (Basel) 2004;116:169.
10. Zhang H, Snyder KM, Suhoski MM, et al. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. J Immunol 2007; 179:4910.
11. Fourcade J, Kudela P, Sun Z, et al. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol 2009;182:5240.
12. Zheng R, Cohen PA, Paustian CA, et al. Paired Tolllike receptor agonists enhance vaccine therapy through induction of interleukin-12. Cancer research 2008; 68:4045.
13. Cho EI, Tan C, Koski GK, et al. Toll-like receptor agonists as third signals for dendritic cell-tumor fusion vaccines. Head Neck 2010;32:700.
14. Hsieh CS, Macatonia SE, Tripp CS, et al. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993;260:547.
15. Yoo JK, Cho JH, Lee SW, Sung YC. IL-12 provides proliferation and survival signals to murine CD4+ T cells through phosphatidylinositol 3-kinase/Akt signaling pathway. J Immunol 2002;169:3637.
16. Valenzuela JO, Hammerbeck CD, Mescher MF. Cutting edge: Bcl-3 up-regulation by signal 3 cytokine (IL-12) prolongs survival of antigen-activated CD8 T cells. J Immunol 2005; 174:600.
17. Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997; 159:4772.
18. Steinbrink K, Jonuleit H, Muller G, et al. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood 1999;93:1634.
19. Leonard JP, Sherman ML, Fisher GL, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997;90: 2541.
20. Car BD, Eng VM, Lipman JM, Anderson TD. The toxicology of interleukin-12: a review. Toxicol Pathol 1999;27:58.
21. Del Vecchio M, Bajetta E, Canova S, et al. Interleukin-12: biological properties and clinical application. Clinical cancer research: an official journal of the American Association for Cancer Research 2007;13:4677.
22. Heinzerling L, Burg G, Dummer R, et al. Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. Hum Gene Ther 2005;16:35.
23. Zhao X, Bose A, Komita H, et al. Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens. Mol Ther 2011; 19:805.
24. Cavallo F, Signorelli P, Giovarelli M, et al. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst 1997;89:1049.
25. Mazzolini G, Alfaro C, Sangro B, et al. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol 2005;23:999.
26. Kerkar SP, Muranski P, Kaiser A, et al. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer research 2010;70:6725.
27. Zitvogel L, Tahara H, Robbins PD, et al. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J Immunol 1995;155:1393.
28. Maldonado V, Melendez-Zaigla J. A modified method for cloning adherent mammalian cells. Bioquimia 2007;32:70.
29. Hung K, Hayashi R, Lafond-Walker A, et al. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998;188:2357.
30. Caignard A, Guillard M, Cai Z, et al. The renal cell carcinoma lysis by a specific cytotoxic T cell clone is independent of the Fas/Fas-L cytotoxic pathway. Tissue Antigens 1996;48:295.
31. Seliger B, Hammers S, Hohne A, Zeidler R, Knuth A, et al. IFN-gamma-mediated coordinated transcriptional regulation of the human TAP-1 and LMP-2 genes in human renal cell carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research 1997;3:573.
32. Mumberg D, Monach PA, Wanderling S, Philip M, Toledano AY, et al. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci USA 1999;96:8633.
33. Cui J, Shin T, Kawano T, et al. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 1997;278: 1623.
34. Voest EE, Kenyon BM, O'Reilly MS, et al. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995;87:581.
35. Indrova M, Bieblova J, Rossowska J, et al. HPV 16-associated tumours: IL-12 can repair the absence of cytotoxic and proliferative responses of tumour infiltrating cells after chemotherapy. Int J Oncol 2009;34:173.
36. Kerkar SP, Goldszmid RS, Muranski P, et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. The Journal of clinical investigation 2011;121:4746.
37. Zheng R, Kjaergaard J, Lee WT, Cohen PA, Shu S. Significance of regional draining lymph nodes in the development of tumor immunity: implications for cancer immunotherapy. Cancer Treat Res 2007;135:223.
38. Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. The American journal of pathology 1999;154:745.
39. Agrawal S, Reemtsma K, Bagiella E, Oluwole SF, Braunstein NS. Role of TAP-1 and/or TAP-2 antigen presentation defects in tumorigenicity of mouse melanoma. Cell Immunol 2004;228:130.
40. Zhang H, Melamed J, Wei P, et al. Concordant down-regulation of proto-oncogene PML and major histocompatibility antigen HLA class I expression in high-grade prostate cancer. Cancer Immun 2003;3:2.
41. Zheng P, Guo Y, Niu Q, et al. Proto-oncogene PML controls genes devoted to MHC class I antigen presentation. Nature 1998;396:373.